Related Experiment Video
Updated: Jul 11, 2026
05:49
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
A new macromolecular paramagnetic MR contrast agent binds to activated human platelets.
Frédéric Chaubet1, Isabelle Bertholon, Jean-Michel Serfaty
1Inserm, U698, Cardiovascular Bio-engineering, CHU X. Bichat, University Paris 7, Paris, France. fchaubet@galilee.univ-paris13.fr
Contrast Media & Molecular Imaging
|September 11, 2007
Summary
A novel biomimetic magnetic resonance contrast agent, CM8FS, selectively binds to activated platelets. This development shows promise for molecular imaging of cardiovascular diseases like atherosclerosis.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Medical Imaging
Background:
- P-selectin glycoprotein ligand-1 (PSGL-1) on activated platelets plays a role in cardiovascular diseases.
- Developing targeted contrast agents for molecular imaging of platelet activation is crucial.
Purpose of the Study:
- To synthesize and characterize a novel functionalized macromolecular magnetic resonance contrast agent.
- To evaluate the agent's specificity for activated platelets in vitro.
- To explore its potential for molecular imaging of activated platelets.
Main Methods:
- Carboxymethylation of dextran followed by fluorolabeling and sulfation to create CM8FS.
- Characterization of CM8FS properties including molecular weight, hydrodynamic radius, and relaxivity.
- Flow cytometry to assess binding affinity to activated human platelets.
- Magnetic Resonance (MR) imaging of activated platelets incubated with CM8FS.
Main Results:
- The synthesized CM8FS agent demonstrated high relaxivity and a molecular weight of 27,000 g/mol.
- CM8FS selectively bound to TRAP-activated human platelets, not resting platelets or other blood cells.
- MR imaging detected a signal from activated platelets incubated with CM8FS.
Conclusions:
- The developed fluorescent paramagnetic contrast agent, CM8FS, effectively recognizes activated human platelets.
- This biomimetic approach offers a promising platform for developing new contrast agents for molecular imaging.
- Potential applications include imaging activated platelets in cardiovascular diseases such as atherosclerosis and aneurysms.
Related Concept Videos
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:24Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...